Mankind (MNKD) shares Plunge after FDA Approves Afrezza, Mankind Inhaled Insulin for Diabetes patients

FDA has approved a new diabetes medication yesterday. The newly approved diabetic drug can be inhaled by the patients. Mankind inhaled insulin was approved by Food and Drug Administration and is called Afrezza.

ManKind Corporation is the manufacturer of the drug Afrezza.

Mankind Inhaled Insulin Afrezza

Afrezza is a fast acting medicine which can be inhaled. It acts like insulin and helps the patients to maintain blood glucose level.

It is already a known fact that diabetes is a chronic condition in which body is unable to secrete enough insulin to maintain the blood sugar levels.

ManKind’s insulin, the newly approved Afrezza, comes in the form of insulin powder. The manufacturers have suggested that it can be inhaled during meal or just before beginning the meal.

However there is a caution issued by FDA with relation to Mankind’s Afrezza.

The patients who are suffering from pre-existing lung diseases or conditions related to lung diseases like broncholitis, pneumonia or asthma are restricted to use the inhaled diabetic medication. There were reports of breathing spasms among these diabetic patients

Mankind (MNKD) shares plunged to 20% during Friday’s trading session after FDA mentioned that the drug Afrezza can’t replace the existing long-term insulin dose and there are some associated risks among the patients related to pulmonary diseases.